论文部分内容阅读
目的探讨维吾尔族和汉族慢性丙型肝炎患者应用聚乙二醇干扰素(PEG-IFN)α-2a联合利巴韦林抗病毒治疗获得SVR的影响因素,为维吾尔族和汉族慢性丙型肝炎的治疗提供依据。方法回顾性分析2012年1月-2014年3月在和田地区传染病专科医院应用PEG-IFNα-2a联合利巴韦林抗病毒治疗的160例丙型肝炎患者的临床资料,其中维吾尔族80例,汉族80例。治疗48周后,随访24周。对两组患者快速病毒学应答(RVR)、早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)、持续病毒学应答(SVR)、无应答(NR)率进行比较,选择可能影响两组患者获得SVR的因素,进行Logistic单因素和多因素回归分析。符合正态分布的计量资料组间比较采用t检验,不符合正态分布则采用Wilcoxon秩和检验;计数资料组间比较采用χ2检验。结果维吾尔族和汉族患者RVR、EVR、ETVR、SVR、NR率分别为48.8%、53.8%、72.5%、63.8%、27.5%和60.0%、63.8%、78.7%、72.5%、21.3%,两组以上指标比较差异均无统计学意义(P值均>0.05)。单因素分析显示,年龄、>40岁为所有患者获得SVR的影响因素。>40岁、HCV RNA定量>1×106拷贝/ml为维吾尔族患者获得SVR的影响因素;男性、年龄及>50岁为汉族患者获得SVR的影响因素。进一步多因素分析显示,维吾尔族患者>40岁、HCV RNA定量>1×106拷贝/ml为其获得SVR的影响因素;汉族患者>50岁、男性为其获得SVR的影响因素。结论维吾尔族和汉族应用PEG-IFNα-2a联合利巴韦林治疗慢性丙型肝炎效果无明显差异。年龄>40岁、HCV RNA定量>1×106拷贝/ml不利于维吾尔族患者获得SVR,年龄>50岁、男性不利于汉族患者获得SVR。
Objective To investigate the influencing factors of SVR in patients with Uigur and Han chronic hepatitis C treated with pegylated interferon (PEG-IFN) -2a and ribavirin, and to investigate the influencing factors of SVR in Uygur and Han patients with chronic hepatitis C Provide the basis for treatment. Methods The clinical data of 160 patients with hepatitis C treated with PEG-IFNα-2a and ribavirin were analyzed retrospectively from January 2012 to March 2014 in Hetian Inpatient Hospital of Infectious Diseases. Among them, 80 cases of Uygur , Han 80 cases. After 48 weeks of treatment, follow up for 24 weeks. The rapid virological response (RVR), early virological response (EVR), virological response (ETVR), continuous virological response (SVR) and non-response (NR) Two groups of patients obtained SVR factors, Logistic single factor and multivariate regression analysis. The t test was used to compare the measurement data between the normal distribution and the Wilcoxon rank sum test which did not meet the normal distribution. The count data were compared between groups using the χ2 test. Results The rates of RVR, EVR, ETVR, SVR and NR in patients with Uygur and Han were 48.8%, 53.8%, 72.5%, 63.8%, 27.5% and 60.0%, 63.8%, 78.7%, 72.5% and 21.3% There was no significant difference between the above indexes (P> 0.05). Univariate analysis showed that age,> 40 years of age for all patients to obtain SVR factors. > 40 years of age, HCV RNA quantification> 1 × 106 copies / ml for Uygur patients to obtain SVR influencing factors; male, age and> 50 years old for Han patients SVR impact factors. Further multivariate analysis showed that Uygur patients> 40 years of age, HCV RNA quantification> 1 × 106 copies / ml for the acquisition of SVR influencing factors; Han patients> 50 years old, men as the SVR influencing factors. Conclusions The effect of PEG-IFNα-2a and ribavirin in treatment of chronic hepatitis C in Uygur and Han nationality has no significant difference. Aged> 40 years old, HCV RNA quantification> 1 × 106 copies / ml is not conducive to obtaining SVR in Uighur patients, aged> 50 years, male is not conducive to SVR in Han patients.